目的 探讨痰热清胶囊联合桉柠蒎肠溶胶囊治疗支气管扩张症的临床疗效。方法 回顾性分析上海交通大学医学院附属第六人民医院2021年1月—2024年12月收治的支气管扩张症急性加重患者150例，根据实际用药情况分为对照组（75例）和治疗组（75例）。两组患者在常规治疗基础上均口服桉柠蒎肠溶胶囊，0.3 g/次，3次/d，治疗组在此基础上同时口服痰热清胶囊，3粒/次，3次/d。两组患者均连续服用2周。评估两组患者治疗效果，比较治疗前后两组患者圣乔治呼吸问卷评分、肺功能、炎症指标、动脉血气。结果 治疗后，治疗组总有效率（93.33%）明显高于对照组（78.67%，P＜0.05）。与对照组比较，治疗组治疗后临床好转时间明显缩短（P＜0.05）。治疗后，治疗组圣乔治呼吸问卷各维度评分均低于对照组（P＜0.05）。治疗后，两组FEV1、FVC、PEF、FEV1/pre%、FEV1/FVC%、PEF/pre%较同组治疗前均升高（P＜0.05），且治疗后治疗组这些指标均高于对照组（P＜0.05）。治疗后，两组患者CRP、IL-17及TNF-α均明显降低（P＜0.05），IFN-γ明显升高（P＜0.05），且治疗后治疗组炎症指标显著好于对照组（P＜0.05）。治疗后，两组pO₂比治疗前升高（P＜0.05），pCO₂降低（P＜0.05），且治疗后治疗组的pO₂高于对照组（P＜0.05），pCO₂低于对照组（P＜0.05）。结论 痰热清胶囊联合桉柠蒎肠溶胶囊协同治疗支气管扩张症，能减轻气道炎症反应，改善肺功能和动脉血气指标，有利于提高疗效。

Objective To explore the clinical efficacy of Tanreqing Capsules combined with Eucalyptus Limonene and Pinene Enteric Capsules in treatment of bronchiectasis. Methods A retrospective analysis was performed on 150 patients with acute exacerbation of bronchiectasis admitted to Shanghai Sixth People’s Hospital Affiliated to Shanghai Jiao Tong University School of Medicine from January 2021 to December 2024. According to the actual medication status, the patients were divided into the control group (75 cases) and the treatment group (75 cases). On the basis of conventional treatment, both groups were orally administered Eucalyptus Limonene and Pinene Enteric Capsules at a dose of 0.3 g per time, three times daily. On this basis, the treatment group was additionally orally administered Tanreqing Capsules, 3 capsules per time, three times daily. Both groups took the medication continuously for 2 weeks. The therapeutic effects of the two groups were evaluated, and the St. George’s Respiratory Questionnaire (SGRQ) scores, lung function indicators, inflammatory indicators, and arterial blood gas indexes before and after treatment were compared between the two groups. Results After treatment, the total effective rate of the treatment group was 93.33%, which was significantly higher than that of the control group (78.67%, P < 0.05). Compared with the control group, the clinical improvement time of the treatment group after treatment was significantly shortened (P < 0.05). After treatment, the scores of all dimensions of the SGRQ in the treatment group were significantly lower than those in the control group (P < 0.05). After treatment, forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC), peak expiratory flow (PEF), FEV1/predicted value (FEV1/pre%), FEV1/FVC ratio (FEV1/FVC%), and PEF/predicted value (PEF/pre%) in both groups were significantly higher than those before treatment in the same group (all P < 0.05), and these indicators in the treatment group were significantly higher than those in the control group after treatment (P < 0.05). After treatment, C-reactive protein (CRP), interleukin-17 (IL-17), and tumor necrosis factor-α (TNF-α) in both groups were significantly decreased (P < 0.05), and interferon-γ (IFN-γ) was significantly increased (all P < 0.05); moreover, the inflammatory indicators of the treatment group were significantly better than those of the control group after treatment (P < 0.05). After treatment, partial pressure of oxygen (pO₂) in both groups was significantly higher than that before treatment (all P < 0.05), and partial pressure of carbon dioxide (pCO₂) was significantly lower than that before treatment (all P < 0.05); in addition, pO₂ in the treatment group was significantly higher than that in the control group after treatment (P < 0.05), and pCO₂ was significantly lower than that in the control group (P < 0.05). Conclusion The combined application of Tanreqing Capsules and Eucalyptol, Limonene and Pinene Enteric Capsules in the treatment of bronchiectasis can alleviate airway inflammatory response, improve lung function and arterial blood gas indexes, and is conducive to enhancing the therapeutic effect.

R974